Peter Gassner

Founder, CEO

Peter Gassner is the visionary behind Veeva, one of the world’s most successful and innovative cloud software companies. He pioneered the industry cloud category when he founded Veeva in 2007 with the belief that vertical cloud software would be the next wave of cloud innovation. Today, Veeva helps more than 600 life sciences companies bring new medicines and treatments to patients faster.

With nearly 30 years of industry experience, Peter has been at the forefront of every major transition in enterprise software, from the mainframe at IBM Silicon Valley Lab, to client-server at PeopleSoft, the cloud at Salesforce, and industry cloud software at Veeva. He was a visionary force behind three of the industry’s most successful enterprise application platforms: Veeva Vault, Salesforce platform, and PeopleTools.

Peter is an advocate for customer and employee success, as well as a passionate industry leader for employee rights and fighting non-compete agreements as an unfair business practice. Through his leadership, Veeva has been widely recognized as one of the world’s top growth companies, including the Fortune Future 50, Forbes Fast Tech 25, and Fortune 100 Fastest-Growing Companies.

Peter currently serves on the board of directors of Veeva and Zoom, and served on the board of directors of Guidewire Software from 2015 to 2019. He holds a bachelor of science degree in computer science from Oregon State University.

Gordon Ritter


Gordon Ritter is chairman of Veeva Systems.

Gordon Ritter is a founder and general partner of Emergence Capital. He has spent over 15 years building companies which pioneered new markets including embedded web-based interfaces, server appliances, "on demand" services for the SMB market and web-native application development. He led Emergence's first investment in the on demand leader, Gordon was named to the Forbes' Midas List of the top venture capital investors in 2007, 2012, 2014, and 2015. He currently sits on the boards of Veeva, Insightly, Top Hat Monocle, High Alpha, Textio, AffectLayer, and Navera. Prior to founding Emergence, Gordon was co-founder and CEO of Software As Service, a web services platform company he created with Marc Benioff, the chairman and CEO of Software As Service is the origin of's Salesforce 1 platform. Prior to forming Software As Service, he was vice president of the $3 billion IBM global small business division, created as a result of IBM's acquisition of his company, Whistle Communications, in 1999. Gordon's division was responsible for partnerships with dozens of technology-enabled service companies as part of IBM's on demand computing strategy. He led IBM's launch partnership with Prior to IBM, Gordon was co-founder and president of Whistle, a pioneering internet appliance and services platform for small and medium-sized businesses. Gordon has a bachelor of arts degree in economics from Princeton University.

Mark Carges


Mark Carges serves on the board of directors of Splunk, Magnet Systems, and Phase One A/S.

He was previously chief technology officer at eBay Inc. from 2009 to 2014, and served on their leadership team since 2008, overseeing eBay Inc.’s platform strategy, as well as having overall responsibility for technology, software development, and site operations for Since 2017, Mark also serves as Senior Advisor at Generation Investment Management.

Prior to joining eBay Inc., Mark was at BEA Systems, a provider of enterprise application infrastructure software which was acquired by Oracle in 2008. During more than a decade at BEA, Mark held a variety of senior technology leadership roles, including chief technology officer.

He began his career at Bell Labs as one of the original architects of Tuxedo, software for constructing highly scalable transaction processing applications. Mark holds a bachelor of arts from the University of California at Berkeley and a master of science degree from New York University.

Paul Chamberlain


Paul Chamberlain works as an advisor, board member, and investor in technology companies. Paul was with Morgan Stanley for more than 25 years. He served as managing director for 18 years, during which time he was the co-head of global technology banking for 10 years. He also served as a member of the investment banking division’s operations committee. During his tenure at Morgan Stanley, Paul participated in many of the most significant IPOs and acquisitions in the technology industry. Since 2015, Paul has operated his own strategic and financial advisory firm, PEC Ventures. He also serves on the board of directors of ServiceNow and TriNet Group.

Paul earned a bachelor of arts degree in history magna cum laude from Princeton University in 1985, and he received an MBA from Harvard Business School in 1989. He serves as chairman of the strategic advisory committee of JobTrain, the Menlo Park, CA-based vocational and life skills training group focused on the neediest in the Silicon Valley community, and he served on its board for over 10 years. Paul regularly lectures in economics and entrepreneurial management classes at Stanford and Princeton Universities.

Mary Lynne Hedley


Dr. Mary Lynne Hedley is a scientist, entrepreneur, biotechnology executive and corporate director with 25 years of experience working in the life science industry. She also currently serves on the board of directors of biopharmaceutical company, Millendo Therapeutics, Inc.

She most recently served as president and chief operating officer at TESARO, an oncology-focused pharmaceutical company she co-founded in 2010 and that was acquired by GSK in 2019. Prior to that she served as executive vice president of operations and chief scientific officer at biotechnology company, Abraxis BioScience, Inc. She was also executive vice president of Eisai Corporation of North America following the company’s acquisition of MGI PHARMA, Inc. Before that she served in various positions at MGI PHARMA, Inc., most recently as executive vice president and chief scientific officer. Dr. Hedley also co-founded and served as the president and CEO of ZYCOS, Inc., a biotechnology company that was acquired by MGI PHARMA, Inc. in 2004.

She has previously served on the board of directors of TESARO, Inc., bluebird bio, and Receptos, Inc., which was acquired by Celgene Corp. in August 2015.

Dr. Hedley received a bachelor of science in microbiology from Purdue University and a Ph.D. in Immunology from the University of Texas, Southwestern Medical Center.

Paul Sekhri


Paul Sekhri has more than 25 years’ experience in life sciences, having served in executive leadership positions at some of the most widely regarded pharmaceutical companies in the world. He is President and CEO of eGenesis, a biotechnology company focused on xenotransplantation. Previously, Paul served as president and CEO of Lycera, an innovative biopharmaceutical company focused on treatments for autoimmune diseases and cancer. Prior to Lycera, he was operating partner at Highline Therapeutics, a biotech incubator launched by Versant Ventures. Paul also served as senior vice president, integrated care at Sanofi where he led the creation of innovative solutions and business models to meet patient needs. Before Sanofi, Paul led global business development and was chief strategy officer at Teva. He also served as operating partner and head, biotech ops group at TPG Biotech, the life sciences venture arm of the global private investment firm TPG, where he was responsible for a portfolio of more than 50 life sciences companies. He has held the roles of founder, president, and chief executive officer of Cerimon Pharmaceuticals; president and chief business officer of ARIAD Pharmaceuticals; and partner for healthcare investments of New Leaf Ventures. Paul spent four years at Novartis, where he held various senior positions, including senior vice president, head of global search and evaluation, business development and licensing, and global head, early commercial development, where he developed the disease area strategy, and founded the early commercial development department.

Paul has served as a director on more than 24 private and public company boards, including BiomX, Ipsen, Compugen, Alpine Immune Sciences, Pharming N.V., Topas Therapeutics, Petra Pharma Corporation, Enumeral Biomedical Holdings, Inc., KAI Pharmaceuticals, Intercept Pharmaceuticals, Macrogenics, PatientSafe Solutions, Tandem Diabetes, and as board advisor to IMS Health.

Paul completed post-graduate studies in clinical anatomy and neuroscience at the University of Maryland, School of Medicine and received his bachelor of science degree in zoology from the University of Maryland, College Park.

Matt Wallach


As co-founder of Veeva and its president until 2019, Matt Wallach helped build the company into one of the most valued and trusted partners to the world’s largest pharmaceutical companies and emerging biotechs. With almost 20 years of life sciences expertise, he played a pivotal role in helping meet customers’ most pressing global requirements in developing and bringing products to market.

Prior to Veeva, Matt held leadership positions in product management, marketing, and business development at various healthcare technology companies. Earlier in his career, Matt was the general manager of the pharmaceuticals & biotechnology division at Siebel Systems, where he established the company as the market leader in Pharma CRM and clinical trial management systems (CTMS) before its acquisition by Oracle.

Matt also serves on the board of directors of HealthVerity. He received an MBA from Harvard Business School and a bachelor of science in economics from Yale University.